{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bleeding+Disorder&page=17",
    "query": {
      "condition": "Bleeding Disorder",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1912,
    "total_pages": 192,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bleeding+Disorder&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bleeding+Disorder&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T10:00:54.197Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02935751",
      "title": "Apixaban Discontinuation Prior to Major Surgery",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemorrhage",
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Lab tests for plasma levels of apixaban and anti-10a factor",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 130,
      "start_date": "2016-10",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2018-09-12",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02935751"
    },
    {
      "nct_id": "NCT01385189",
      "title": "Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hookworm Infection",
        "Hookworm Disease"
      ],
      "interventions": [
        {
          "name": "10 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "100 μg Na-GST-1/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-05",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2025-01-06",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01385189"
    },
    {
      "nct_id": "NCT00009620",
      "title": "Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infant, Newborn",
        "Infant, Low Birth Weight",
        "Infant, Small for Gestational Age",
        "Infant, Premature",
        "Intracranial Hemorrhages"
      ],
      "interventions": [
        {
          "name": "Phenobarbital",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 610,
      "start_date": "1993-02",
      "completion_date": "1997-02",
      "has_results": false,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 11,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00009620"
    },
    {
      "nct_id": "NCT05468320",
      "title": "Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "anti-CD20 antibody",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2022-11-21",
      "completion_date": "2024-12-26",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05468320"
    },
    {
      "nct_id": "NCT06371417",
      "title": "Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antiphospholipid Syndrome (APS)",
        "Bullous Pemphigoid (BP)",
        "Behçet's Syndrome (BS)",
        "Dermatomyositis (DM)",
        "Immune-mediated Necrotizing Myopathy (IMNM)",
        "Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "RAY121",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chugai Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 144,
      "start_date": "2024-08-19",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 11,
      "location_summary": "Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06371417"
    },
    {
      "nct_id": "NCT02011321",
      "title": "Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Subarachnoid Hemorrhage",
        "Cerebral Aneurysm",
        "Vasospasm, Intracranial"
      ],
      "interventions": [
        {
          "name": "clevidipine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-03",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02011321"
    },
    {
      "nct_id": "NCT04431726",
      "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "0 Months to 12 Months"
      },
      "enrollment_count": 55,
      "start_date": "2021-02-04",
      "completion_date": "2030-05-18",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04431726"
    },
    {
      "nct_id": "NCT02893826",
      "title": "Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Subarachnoid Hemorrhage, Aneurysmal"
      ],
      "interventions": [
        {
          "name": "EG-1962 (nimodipine microparticles)",
          "type": "DRUG"
        },
        {
          "name": "Enteral Nimodipine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edge Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2016-09",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • San Francisco, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02893826"
    },
    {
      "nct_id": "NCT02548143",
      "title": "LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Coagulation Factor VIIa (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Laboratoire français de Fractionnement et de Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "6 Months to 75 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2016-08-25",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2022-02-25",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548143"
    },
    {
      "nct_id": "NCT01333111",
      "title": "Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia B"
      ],
      "interventions": [
        {
          "name": "nonacog beta pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "13 Years to 70 Years · Male only"
      },
      "enrollment_count": 74,
      "start_date": "2011-04-27",
      "completion_date": "2013-03-31",
      "has_results": true,
      "last_update_posted_date": "2017-07-28",
      "last_synced_at": "2026-10-22T10:00:54.197Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Augusta, Georgia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01333111"
    }
  ]
}